Volume 2.30 | Aug 3

Mesenchymal Cell News 2.30, August 3, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Revolutionary Findings Prove Novel Mechanism of Stem Cells 
Miller School researchers have demonstrated exactly how mesenchymal stem cells from bone marrow can repair the heart – a critical step in stem cell research that could in the near future help millions of patients with heart failure. [Press release from the University of Miami Miller School of Medicine discussing online prepublication in Circulation Research]

MesenCult®-XF Medium  
Obtain more MSCs in fewer passages with
MesenCult®-XF Medium

by STEMCELL Technologies


NIH-Funded Researchers Make Progress Toward Regenerating Tissue to Replace Joint  
A team of NIH-funded researchers has successfully regenerated rabbit joints using a cutting edge process to form the joint inside the body, or in vivo. [Press release from the National Institutes of Health discussing online prepublication in The Lancet]

Stem Cell Transplant Benefits Severe Lupus
Allogeneic mesenchymal stem cell transplantation resulted in improvements in disease activity, serologic markers, and renal function in patients with refractory systemic lupus erythematosus, a pilot study conducted in China found. [Press release from Medpage Today discussing online prepublication in the Annals of the Rheumatic Diseases]

Scientists at University of Colorado Anschutz Medical Campus Discover New Fat Cell
A research team at the University of Colorado School of Medicine has discovered a new type of fat cell with potentially harmful characteristics. [Press release from the University of Coloardo Anschutz Medical Campus discussing online prepublication in Proceedings of the National Academy of Sciences USA]


Learn about our GLP compliant Contract Assay Services


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Regeneration of the Articular Surface of the Rabbit Synovial Joint by Cell Homing: a Proof of Concept Study
Scientists tested the hypothesis that the articular surface of the synovial joint can regenerate with a biological cue spatially embedded in an anatomically correct bioscaffold. [Lancet]

Effect of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in a PolyI:C-Induced Primary Biliary Cirrhosis Mouse Model
Researchers established a primary biliary cirrhosis animal model by injecting C57BL/6 mice with polyinosinic-polycytidylic acid sodium (polyI:C) to investigate the therapeutic effect of bone marrow-derived mesenchymal stem cells on this model. [Clin Exp Med]

De Novo Generation of White Adipocytes from the Myeloid Lineage via Mesenchymal Intermediates is Age, Adipose Depot, and Gender Specific
It is generally assumed that white adipocytes arise from resident adipose tissue mesenchymal progenitor cells. Scientists challenged this paradigm by defining a hematopoietic origin for both the de novo development of a subset of white adipocytes in adults and a previously uncharacterized adipose tissue resident mesenchymal progenitor population. [Proc Natl Acad Sci USA]

Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation
Here, investigators tested the hypothesis that bone marrow derived mesenchymal stem cells stimulate the proliferation and differentiation of endogenous cardiac stem cells as part of their regenerative repertoire. [Circ Res]

Allogenic Mesenchymal Stem Cells Transplantation in Refractory Systemic Lupus Erythematosus: a Pilot Clinical Study
The objective of this study was to determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation in refractory systemic lupus erythematosus. [Ann Rheu Dis]

Reactive Bone Marrow Stromal Cells Attenuate Systemic Inflammation via sTNFR1
Scientists hypothesized that mesenchymal stem cells can dynamically secrete systemic factors that can neutralize the activity of inflammatory cytokines. [Mol Ther]

Mesenchymal Stem Cells Inhibit Both Endogenous and Exogenous MMPs Via Secreted TIMPs
Here, investigators focused on the mesenchymal stem cell contribution of key regulators of the perivascular niche, the matrix metalloproteinases (MMPs) and their inhibitors, the TIMPs. [J Cell Physiol]

Epigenetic Upregulation of Urokinase Plasminogen Activator Promotes the Tropism of Mesenchymal Stem Cells for Tumor Cells
Researchers investigated whether histone deacetylation was involved in the repression of urokinase plasminogen activator expression in mesenchymal stem cells derived from umbilical cord blood and bone marrow. [Mol Cancer Res]

Histone Modifiers, YY1 and p300, Regulate the Expression of Cartilage-Specific Gene, Chondromodulin-I, in Mesenchymal Stem Cells
In this study, scientists investigated the molecular mechanisms of the down-regulation of chondromodulin-I expression in mesenchymal stem cells and normal mesenchymal tissues other than cartilage. [J Biol Chem]

A Novel Biomimetic Composite Scaffold Hybridized with Mesenchymal Stem Cells in Repair of Rat Bone Defects Models
In this study, the in vivo bone-regenerative potential of a novel bioactive glass-collagen-hyaluronic acid-phosphatidylserine composite scaffold hybridized with mesenchymal stem cells was investigated in a rat bone defect model. [J Biomed Mater Res A]


Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair
Cytori Therapeutics received expanded European approval (CE Mark) for its Celution(R) System, a medical device that extracts and separates stem and regenerative cells from a patient’s own fat tissue. [Cytori Therapeutics Press Release]

Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech
Charles River Laboratories International, Inc. announced that it has mutually agreed with WuXi PharmaTech Inc. to terminate their previously announced acquisition agreement. [Charles River Laboratories International, Inc. Press Release]

British Companies to Receive Support to Develop New Regenerative Medicine Products and Technologies
The government-backed Technology Strategy Board is to invest over £5 million to support the research and development in the UK of new regenerative medicine products, tools and technologies. 16 research and development projects in the field of regenerative medicine therapeutics are to receive a total of £3.6 million of investment, while a further £1.6 million is to be invested in 12 feasibility studies in the area of regenerative medicine tools and technologies. [Technology Strategy Board Press Release]


MHRA Business Plan 2010 and Corporate Plan 2010-15 Published
The MHRA gained ministerial agreement for the Agency’s Business Plan 2010 and the Corporate Plan 2010-15. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Regulation of Advanced Therapy Medicinal Products in the UK
The statutory instrument for implementing the UK’s requirements under the hospital exemption scheme (The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010) was laid in Parliament on 26 July 2010. [Medicines and Healthcare Products Regulatory Agency, United Kingdom] 

Biomedical Advanced Research and Development Authority (BARDA) Exercises $4.1 Million Fourth Option on Cleveland BioLabs Contract to Develop Radiation Countermeasure CBLB502
Cleveland BioLabs, Inc. announced that the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services exercised the $4.1 million fourth milestone-based option on the Company’s existing contract under the Broad Agency Announcement titled, “Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation,” for selected tasks in the advanced development of Protectan CBLB502. [Biomedical Advanced Research and Development Authority, United States]

Risk Evaluation and Mitigation Strategy (REMS) Public Meeting
The Food and Drug Administration announced a 2-day public meeting to obtain input on issues and challenges associated with the development and implementation of risk evaluation and mitigation strategies for drugs. An archived webcast of the meeting is available. [Food and Drug Administration, United States]

NSF Funding Request Faring Well in Congress
While the 2011 budget requests of other U.S. research agencies are struggling to stay afloat in choppy fiscal seas, so far National Science Foundation’s (NSF) is sailing through Congress largely intact. [National Science Foundation, United States]

Senate Spending Panel Approves $1 Billion Boost for NIH
A Senate subcommittee matched President Barack Obama’s request for a $1 billion increase in 2011 for the National Institutes of Health (NIH). That raise would bring the agency’s total budget to $32 billion, or 3.5% above the 2010 level, according to a statement from the Senate appropriations labor, health, and human services subcommittee. [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (Doc. 2010-18627)  [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting [2010-18385] [National Institutes of Health, United States]

Correction of Major Programmatic Priorities for RFA-HL-11-025 (R01); “New Strategies for Growing 3D Tissues” (NOT-HL-11-115) [National Institutes of Health, United States]

Agency Information Collection Activities: Proposed Collection; Comment Request [Agency for Healthcare Research and Quality, United States]

EVENTS (Listed by Date)

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

NEW Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States   

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

NEW bone-tec 2010 – International Bone-Tissue Engineering Congress
October 7-10, 2010
Hannover, Germany

5th Annual Germany Society for Stem Cell Research
September 30-October 2, 2010
Lübeck, Germany

2010 World Stem Cell Summit
October 4-6, 2010
Detroit, United States

5th World Congress on Preventative and Regenerative Medicine (WCRM) 2010
October 5-7, 2010
Hannover, Germany

International Federation of Adipose Therapeutics & Science (IFATS) 2010 Conference
October 22-24, 2010
Dallas, United States

2010 American Society for Matrix Biology (ASMB) Meeting
October 24-27, 2010
Charleston, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference
December 5-8, 2010
Orlando, United States

Epithelial Plasticity and Epithelial to Mesenchymal Transition (A8)
January 21-26, 2011
Vancouver, Canada

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington DC, United States

Stem Cells, Cancer and Metastasis (C4)
March 6-11, 2011
Dillon, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Mesenchymal Cell News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives  |  Events   |  Contact Us